Antibodies | Multifaceted Mechanisms of Anti-TNF-α Antibodies in Inflammatory Bowel Disease

This study systematically reveals multiple immunomodulatory functions of anti-TNF-α antibodies beyond neutralizing soluble TNF-α, providing critical theoretical support for personalized treatment strategies in inflammatory bowel disease (IBD). It suggests that future approaches should comprehensively assess mTNF-α expression and immune cell subset dynamics to optimize biologic selection.

 

Literature Overview

The article titled 'Multiple Modes of Action of Anti-TNF-α Antibodies for Inflammatory Bowel Diseases Beyond TNF-α Neutralization,' published in the journal Antibodies, systematically explores the diverse mechanisms of anti-TNF-α antibodies in the treatment of inflammatory bowel disease (IBD), beyond neutralizing soluble TNF-α (sTNF-α). The paper emphasizes the pathogenic role of membrane-bound TNF-α (mTNF-α) and its superiority as a therapeutic target. By integrating clinical evidence with in vitro experimental data, it elucidates the multiple immunomodulatory functions of anti-TNF-α antibodies—such as adalimumab, infliximab, and golimumab—in inducing and maintaining remission. The article further proposes that these mechanisms collectively form the basis of anti-TNF-α antibody efficacy, far exceeding simple cytokine neutralization.

Background Knowledge

1. The key clinical challenge in IBD addressed by this study is that although multiple biologics are available, some patients do not respond to IL-12/IL-23-targeted therapies, yet still benefit from anti-TNF-α antibodies, suggesting more complex mechanisms of action. The traditional view attributes efficacy to sTNF-α neutralization, but clinical observations show that etanercept—which only neutralizes sTNF-α—is ineffective in IBD, indicating that mTNF-α plays a central role in disease pathogenesis.

2. The current bottleneck in TNF-α research lies in the oversimplification of most TNF-α-targeting therapies as 'cytokine blockers,' neglecting Fc domain-mediated effector functions (such as CDC and ADCC) and their regulatory effects on immune cell fate. Additionally, accurately predicting patient response to anti-TNF-α therapy and explaining how some patients benefit despite no significant elevation in TNF-α expression remain unresolved challenges.

3. The study's conceptual innovation lies in proposing that the clinical advantage of anti-TNF-α antibodies may stem from their direct elimination or reprogramming of immune cells expressing mTNF-α—such as macrophages, dendritic cells, and T cells—including inducing apoptosis, expanding regulatory T cells (Tregs), and promoting regulatory macrophage differentiation. This perspective redefines anti-TNF-α therapy from 'passive neutralization' to 'active immune remodeling,' offering new directions for next-generation biologic development.

 

 

Research Methods and Experiments

The authors conducted a systematic review of three major anti-TNF-α antibodies—adalimumab, golimumab, and infliximab—based on existing preclinical and clinical data, focusing on their mechanisms of action in IBD. The study relied on in vitro cellular models, such as using Jurkat T cells overexpressing mTNF-α as target cells co-cultured with PBMCs to evaluate ADCC activity; complement-dependent cytotoxicity (CDC) was assessed by adding complement components; and apoptosis was analyzed using Annexin V/PI staining. The research also integrated multiple clinical cohort datasets, such as immunofluorescence detection of changes in CD68+ macrophages in the intestinal mucosa of IBD patients, validating the correlation between reduced IL-23p19 expression and mucosal healing after infliximab treatment.

Key findings include: 1) infliximab and adalimumab can significantly induce CDC and ADCC in cells expressing mTNF-α, whereas etanercept cannot; 2) infliximab binding to mTNF-α induces cell cycle arrest and apoptosis via 'outside-in' signaling, dependent on serine residues in the intracellular domain of mTNF-α; 3) increased numbers of FOXP3+ Tregs in the gut and peripheral blood of patients after treatment suggest immune tolerance restoration; 4) infliximab upregulates CD206 and IL-10, indicating induction of regulatory macrophage differentiation.

Key Conclusions and Perspectives

• Anti-TNF-α antibodies eliminate mTNF-α-expressing macrophages and dendritic cells via CDC, significantly reducing pro-inflammatory cytokines such as IL-1β, IL-6, IL-12, and IL-23. This suggests that monitoring the dynamics of these cell subsets should be prioritized in IBD models to evaluate drug efficacy.
• ADCC is a key effector mechanism of anti-TNF-α antibodies, dependent on the IgG1 Fc domain. Therefore, preserving Fc function is essential in the development of novel TNF-α inhibitors to maintain immune clearance capacity.
• Infliximab and adalimumab induce apoptosis in lamina propria T cells, particularly CD4+TNFR2+ T cells, providing a mechanistic basis for their rapid induction of mucosal healing. Future research should explore regulatory nodes in the TNFR2-mTNF-α interaction within T cell signaling pathways.
• Anti-TNF-α antibodies promote Treg expansion, potentially through reverse signaling via mTNF-α and TNFR2, suggesting Tregs could serve as biomarkers of treatment response. In autoimmune disease models, combining anti-TNF-α therapy with Treg-expansion strategies may enhance therapeutic efficacy.
• Infliximab induces a regulatory macrophage phenotype, characterized by upregulation of CD206 and IL-10, though this effect may be complexly regulated by FcγRI activation. This highlights the need to distinguish signal outputs from different immune complexes in macrophage polarization studies.

Research Significance and Prospects

The study's implications for drug development are significant: next-generation anti-TNF-α therapies (e.g., ozoralizumab) may offer improved pharmacokinetics, but if they lack Fc functionality, they may fail to replicate the multifaceted immunomodulatory effects of traditional antibodies. Thus, future designs must balance safety with mechanistic efficacy.

In terms of clinical monitoring, beyond conventional markers such as CRP and fecal calprotectin, mTNF-α expression, Treg frequency, and macrophage polarization status should be explored as more precise predictors of treatment response. Furthermore, confocal endoscopy combined with fluorescently labeled anti-TNF-α antibodies could enable in vivo imaging of TNF-α, potentially serving as a decision-making tool for personalized therapy.

Regarding disease modeling, current IBD animal models often rely on TNF-α overexpression. However, this study suggests that cell-specific expression of mTNF-α—particularly in myeloid cells—may be more critical. Therefore, developing conditional mTNF-α expression models is recommended to more accurately recapitulate human disease mechanisms.

 

 

Conclusion

This study redefines the role of anti-TNF-α antibodies in inflammatory bowel disease, expanding their identity from simple cytokine neutralizers to biologics with multifaceted immunomodulatory functions. Through mechanisms such as CDC, ADCC, apoptosis induction, Treg expansion, and macrophage reprogramming, anti-TNF-α antibodies achieve profound remodeling of the intestinal immune environment. This finding not only explains the inefficacy of etanercept in IBD but also offers new perspectives for optimizing treatment strategies. In the future, precise assessment of mTNF-α cellular sources and the immune microenvironment in patients' intestines will help guide personalized biologic selection. Moreover, developing next-generation anti-TNF-α therapies that combine neutralizing activity with immunomodulatory functions—or combining them with Treg-enhancing strategies—may further improve remission rates. From bench to bedside, this research lays a mechanistic foundation for precision medicine in IBD, underscoring the central role of holistic immune system regulation in managing chronic inflammation. Ultimately, integrating multi-omics data with in vivo imaging technologies will drive the evolution of IBD care toward dynamic, individualized, and mechanism-driven paradigms.

 

Tomohiro Watanabe and Masatoshi Kudo. Multiple Modes of Action of Anti-TNF-α Antibodies for Inflammatory Bowel Diseases Beyond TNF-α Neutralization. Antibodies.